¹⁶¹Tb-PSMA-I&T is a terbium analogue of ¹⁷⁷Lu-Vipivotide tetraxetan and the clinically developed alternative to ¹⁶¹Tb-PSMA-617. The advantage of using Terbium-161 is the possibility to develop analogues of the same Atom in particular the Alpha emitting terbium Isotope ¹⁴⁹Tb. Another advantage of ¹⁶¹Tb, compared to ¹⁷⁷Lu, is linked to its additional emission of Auger/conversion electrons which could translate energy in higher efficacy.
A clinical trial (Phase 0/I) is under preparation at the Peter MacCallum Cancer Centre, Melbourne, Australia.

Target/Mechanism: PSMA

Carrier/Ligand: PSMA-I&T

Radiation Type: beta electrons (β^–)